



PRESS RELEASE

THE INTERIM FINANCIAL REPORT AT 30 JUNE 2018 OF THE PIERREL GROUP HAS BEEN PUBLISHED, INCLUDING THE PIERREL CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AT 30 JUNE 2018

Capua, 31 August 2018 – Pierrel S.p.A. (the “Company”) informs that the interim financial report of the Pierrel Group at 30 June 2018, which includes the condensed consolidated interim financial statements of the Company as at 30 June 2018, approved by the Company's Board of Directors on 29 August 2018, is available to the public - together with the report containing the opinion of the Independent Auditors - at the registered office of the Company, on its website at the address www.pierrelgroup.com, as well as at the authorized storage mechanism Nis-Storage (www.emarketstorage.com).

* * *

Pierrel S.p.A. specialises in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.

Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Mr Fulvio Citaredo

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult s.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665